Control of NK cell function and survival by modulation of ship activity
AssigneeUniversity of South Florida
InventorWilliam Kerr
Life of this patent
Estimating the term…
Abstract
Inhibition of dendritic cell function in solid organ grafts or allogeneic bone marrow transplants prior to or during engraftment by blocking SH2-containing inositol phosphatase (SHIP) expression or function is taught as a method of abrogating immune rejection and thereby increasing the efficacy of engraftment of an allogeneic bone marrow transplant or solid organ allograft or xenograft. Also disclosed is a transgenic mouse having the genotype SHIP−/− which exhibits enhanced survival following mismatched allogeneic marrow grafts.
Claims7
A method for reducing antigen presenting cell (APC) function in a mammal, comprising administering an efficacious amount of interfering RNA specific for SHIP-1 mRNA to the mammal, before or during allogeneic transplantation, wherein the interfering RNA reduces SHIP-1 expression or function and APC function in the mammal, and wherein the mammal is a human or mouse.
A method for reducing antigen presenting cell (APC) function in a mammal, comprising administering an efficacious amount of a nucleic acid molecule to the mammal, before or during allogeneic transplantation, wherein the nucleic acid molecule is an antisense molecule, ribozyme or double-stranded RNA specific for the mammal's SHIP-1 mRNA, wherein the nucleic acid molecule reduces SHIP-1 expression or function and APC function in the mammal, and wherein the mammal is a human or mouse.
A method for reducing antigen presenting cell (APC) function in a human, comprising administering an efficacious amount of a double-stranded RNA molecule to the human, before or during allogeneic transplantation, wherein the double-stranded RNA molecule reduces SHIP-1 expression or function and APC function in the human.
Dependencies are inferred from the claim text.